Differential production of Type I IFN Determines the Reciprocal Levels of IL-10 and proinflammatory cytokines produced by C57BL/6 and BALB/c macrophages

Journal of Immunology

Volumn 197, Issue 7, 2016, Pages 2838-2853

  Howes, Ashleigh ^a   Taubert, Christina ^a   Blankley, Simon ^a   Spink, Natasha ^b   Wu, Xuemei ^a   Graham, Christine M ^a   Zhao, Jiawen ^c   Saraiva, Margarida ^d   Ricciardi Castagnoli, Paola ^e   Bancroft, Gregory J ^b   O'garra, Anne ^a,f  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c Neo Life Stem Cell Biotech Inc   (China)

^d UNIVERSITY OF MINHO   (Portugal)

^e AGENCY FOR SCIENCE   (Singapore)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 27; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; STAT1 PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; CYTOKINE;

ANIMAL CELL; ARTICLE; BAGG ALBINO MOUSE; BONE MARROW DERIVED MACROPHAGE; BURKHOLDERIA PSEUDOMALLEI; C57BL 6 MOUSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOREGULATION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA STABILITY; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; COMPARATIVE STUDY; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM;

ANIMALS; BURKHOLDERIA PSEUDOMALLEI; CYTOKINES; INFLAMMATION; INTERFERON TYPE I; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT;

EID: 84989939029     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501923     Document Type: Article

References (51)

1. Murray, P. J., and S. T. Smale. 2012. Restraint of inflammatory signaling by interdependent strata of negative regulatory pathways. Nat. Immunol. 13: 916- 924.
2. Kawai, T., and S. Akira. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11: 373-384.
3. Moore, K. W., R. de Waal Malefyt, R. L. Coffman, and A. O'Garra. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19: 683- 765.
4. Sellon, R. K., S. Tonkonogy, M. Schultz, L. A. Dieleman, W. Grenther, E. Balish, D. M. Rennick, and R. B. Sartor. 1998. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect. Immun. 66: 5224-5231.
5. Berg, D. J., R. Kuhn, K. Rajewsky, W. Muller, S. Menon, N. Davidson, G. Grunig, and D. Rennick. 1995. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J. Clin. Invest. 96: 2339-2347.
6. Saraiva, M., and A. O'Garra. 2010. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10: 170-181.
7. Fiorentino, D. F., A. Zlotnik, T. R. Mosmann, M. Howard, and A. O'Garra. 1991. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147: 3815-3822.
8. Lang, R., D. Patel, J. J. Morris, R. L. Rutschman, and P. J. Murray. 2002. Shaping gene expression in activated and resting primary macrophages by IL-10. J. Immunol. 169: 2253-2263.
9. Williams, L., L. Bradley, A. Smith, and B. Foxwell. 2004. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J. Immunol. 172: 567-576.
10. Trinchieri, G. 2010. Type I interferon: friend or foe? J. Exp. Med. 207: 2053- 2063.
11. Chang, E. Y., B. Guo, S. E. Doyle, and G. Cheng. 2007. Cutting edge: involvement of the type I IFN production and signaling pathway in lipopolysaccharide-induced IL-10 production. J. Immunol. 178: 6705-6709.
12. Ziegler-Heitbrock, L., M. Lötzerich, A. Schaefer, T. Werner, M. Frankenberger, and E. Benkhart. 2003. IFN-A induces the human IL-10 gene by recruiting both IFN regulatory factor 1 and Stat3. J. Immunol. 171: 285-290.
13. Wang, H., J. Brown, C. A. Garcia, Y. Tang, M. R. Benakanakere, T. Greenway, P. Alard, D. F. Kinane, and M. Martin. 2011. The role of glycogen synthase kinase 3 in regulating IFN-b-mediated IL-10 production. J. Immunol. 186: 675- 684.
14. Guarda, G., M. Braun, F. Staehli, A. Tardivel, C. Mattmann, I. Förster, M. Farlik, T. Decker, R. A. Du Pasquier, P. Romero, and J. Tschopp. 2011. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34: 213-223.
15. Byrnes, A. A., X. Ma, P. Cuomo, K. Park, L. Wahl, S. F. Wolf, H. Zhou, G. Trinchieri, and C. L. Karp. 2001. Type I interferons and IL-12: convergence and cross-regulation among mediators of cellular immunity. Eur. J. Immunol. 31: 2026-2034.
16. McNab, F. W., J. Ewbank, A. Howes, L. Moreira-Teixeira, A. Martirosyan, N. Ghilardi, M. Saraiva, and A. O'Garra. 2014. Type I IFN induces IL-10 production in an IL-27-independent manner and blocks responsiveness to IFN-g for production of IL-12 and bacterial killing in Mycobacterium tuberculosis-infected macrophages. J. Immunol. 193: 3600-3612.
17. McRae, B. L., R. T. Semnani, M. P. Hayes, and G. A. van Seventer. 1998. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J. Immunol. 160: 4298-4304.
18. Gautier, G., M. Humbert, F. Deauvieau, M. Scuiller, J. Hiscott, E. E. Bates, G. Trinchieri, C. Caux, and P. Garrone. 2005. A type I interferon autocrineparacrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J. Exp. Med. 201: 1435-1446.
19. Cousens, L. P., J. S. Orange, H. C. Su, and C. A. Biron. 1997. Interferon-A/b inhibition of interleukin 12 and interferon-g production in vitro and endogenously during viral infection. Proc. Natl. Acad. Sci. USA 94: 634-639.
20. McNab, F., K. Mayer-Barber, A. Sher, A. Wack, and A. O'Garra. 2015. Type I interferons in infectious disease. Nat. Rev. Immunol. 15: 87-103.
21. Sacks, D., and N. Noben-Trauth. 2002. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2: 845-858.
22. Mainou-Fowler, T., A. P. MacGowan, and R. Postlethwaite. 1988. Virulence of Listeria spp.: course of infection in resistant and susceptible mice. J. Med. Microbiol. 27: 131-140.
23. Schluter, D., M. Deckert-Schluter, E. Lorenz, T. Meyer, M. Röllinghoff, and C. Bogdan. 1999. Inhibition of inducible nitric oxide synthase exacerbates chronic cerebral toxoplasmosis in Toxoplasma gondii-susceptible C57BL/6 mice but does not reactivate the latent disease in T. gondii-resistant BALB/c mice. J. Immunol. 162: 3512-3518.
24. Wiersinga, W. J., T. van der Poll, N. J. White, N. P. Day, and S. J. Peacock. 2006. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat. Rev. Microbiol. 4: 272-282.
25. Simpson, A. J., M. D. Smith, G. J. Weverling, Y. Suputtamongkol, B. J. Angus, W. Chaowagul, N. J. White, S. J. van Deventer, and J. M. Prins. 2000. Prognostic value of cytokine concentrations (tumor necrosis factor-A, interleukin-6, and interleukin-10) and clinical parameters in severe melioidosis. J. Infect. Dis. 181: 621-625.
26. Leakey, A. K., G. C. Ulett, and R. G. Hirst. 1998. BALB/c and C57Bl/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animal models for the acute and chronic forms of human melioidosis. Microb. Pathog. 24: 269-275.
27. Titball, R. W., P. Russell, J. Cuccui, A. Easton, A. Haque, T. Atkins, M. Sarkar- Tyson, V. Harley, B. Wren, and G. J. Bancroft. 2008. Burkholderia pseudomallei: Animal models of infection. Trans. R. Soc. Trop. Med. Hyg. 102(Suppl. 1): S111- S116.
28. Tan, G. Y., Y. Liu, S. P. Sivalingam, S. H. Sim, D. Wang, J. C. Paucod, Y. Gauthier, and E. E. Ooi. 2008. Burkholderia pseudomallei aerosol infection results in differential inflammatory responses in BALB/c and C57Bl/6 mice. J. Med. Microbiol. 57: 508-515.
29. Ulett, G. C., N. Ketheesan, and R. G. Hirst. 2000. Cytokine gene expression in innately susceptible BALB/c mice and relatively resistant C57BL/6 mice during infection with virulent Burkholderia pseudomallei. Infect. Immun. 68: 2034- 2042.
30. Ulett, G. C., N. Ketheesan, and R. G. Hirst. 2000. Proinflammatory cytokine mRNA responses in experimental Burkholderia pseudomallei infection in mice. Acta Trop. 74: 229-234.
31. Liu, B., G. C. Koo, E. H. Yap, K. L. Chua, and Y. H. Gan. 2002. Model of differential susceptibility to mucosal Burkholderia pseudomallei infection. Infect. Immun. 70: 504-511.
32. Berg, D. J., N. Davidson, R. Kuhn, W. Muller, S. Menon, G. Holland, L. Thompson-Snipes, M. W. Leach, and D. Rennick. 1996. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4+ TH1-like responses. J. Clin. Invest. 98: 1010-1020.
33. McNab, F. W., J. Ewbank, R. Rajsbaum, E. Stavropoulos, A. Martirosyan, P. S. Redford, X. Wu, C. M. Graham, M. Saraiva, P. Tsichlis, et al. 2013. TPL-2- ERK1/2 signaling promotes host resistance against intracellular bacterial infection by negative regulation of type I IFN production. J. Immunol. 191: 1732- 1743.
34. Bain, J., L. Plater, M. Elliott, N. Shpiro, C. J. Hastie, H. McLauchlan, I. Klevernic, J. S. Arthur, D. R. Alessi, and P. Cohen. 2007. The selectivity of protein kinase inhibitors: A further update. Biochem. J. 408: 297-315.
35. Kaiser, F., D. Cook, S. Papoutsopoulou, R. Rajsbaum, X. Wu, H. T. Yang, S. Grant, P. Ricciardi-Castagnoli, P. N. Tsichlis, S. C. Ley, and A. O'Garra. 2009. TPL-2 negatively regulates interferon-b production in macrophages and myeloid dendritic cells. J. Exp. Med. 206: 1863-1871.
36. Wiersinga, W. J., C. W. Wieland, M. C. Dessing, N. Chantratita, A. C. Cheng, D. Limmathurotsakul, W. Chierakul, M. Leendertse, S. Florquin, A. F. de Vos, et al. 2007. Toll-like receptor 2 impairs host defense in gram-negative sepsis caused by Burkholderia pseudomallei (Melioidosis). PLoS Med. 4: e248.
37. Hii, C. S., G. W. Sun, J. W. Goh, J. Lu, M. P. Stevens, and Y. H. Gan. 2008. Interleukin-8 induction by Burkholderia pseudomallei can occur without Tolllike receptor signaling but requires a functional type III secretion system. J. Infect. Dis. 197: 1537-1547.
38. West, T. E., R. K. Ernst, M. J. Jansson-Hutson, and S. J. Skerrett. 2008. Activation of Toll-like receptors by Burkholderia pseudomallei. BMC Immunol. 9: 46.
39. Kobayashi, M., L. Fitz, M. Ryan, R. M. Hewick, S. C. Clark, S. Chan, R. Loudon, F. Sherman, B. Perussia, and G. Trinchieri. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170: 827-845.
40. Honda, K., H. Yanai, A. Takaoka, and T. Taniguchi. 2005. Regulation of the type I IFN induction: A current view. Int. Immunol. 17: 1367-1378.
41. Pattison, M. J., K. F. Mackenzie, and J. S. Arthur. 2012. Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback. J. Immunol. 189: 2784-2792.
42. Mayer-Barber, K. D., B. B. Andrade, D. L. Barber, S. Hieny, C. G. Feng, P. Caspar, S. Oland, S. Gordon, and A. Sher. 2011. Innate and adaptive interferons suppress IL-1a and IL-1b production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity 35: 1023-1034.
43. Iyer, S. S., A. A. Ghaffari, and G. Cheng. 2010. Lipopolysaccharide-mediated IL-10 transcriptional regulation requires sequential induction of type I IFNs and IL-27 in macrophages. J. Immunol. 185: 6599-6607.
44. Kalliolias, G. D., and L. B. Ivashkiv. 2008. IL-27 activates human monocytes via STAT1 and suppresses IL-10 production but the inflammatory functions of IL-27 are abrogated by TLRs and p38. J. Immunol. 180: 6325-6333.
45. Molle, C., M. Goldman, and S. Goriely. 2010. Critical role of the IFN-stimulated gene factor 3 complex in TLR-mediated IL-27p28 gene expression revealing a two-step activation process. J. Immunol. 184: 1784-1792.
46. Gabrysová, L., A. Howes, M. Saraiva, and A. O'Garra. 2014. The regulation of IL-10 expression. Curr. Top. Microbiol. Immunol. 380: 157-190.
47. Banerjee, A., R. Gugasyan, M. McMahon, and S. Gerondakis. 2006. Diverse Toll-like receptors utilize Tpl2 to activate extracellular signal-regulated kinase (ERK) in hemopoietic cells. Proc. Natl. Acad. Sci. USA 103: 3274-3279.
48. Dillon, S., A. Agrawal, T. Van Dyke, G. Landreth, L. McCauley, A. Koh, C. Maliszewski, S. Akira, and B. Pulendran. 2004. A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-Activated protein kinase and c-Fos in dendritic cells. J. Immunol. 172: 4733-4743.
49. Kim, C., Y. Sano, K. Todorova, B. A. Carlson, L. Arpa, A. Celada, T. Lawrence, K. Otsu, J. L. Brissette, J. S. Arthur, and J. M. Park. 2008. The kinase p38a serves cell type-specific inflammatory functions in skin injury and coordinates pro-And anti-inflammatory gene expression. Nat. Immunol. 9: 1019-1027.
50. Ma, W., W. Lim, K. Gee, S. Aucoin, D. Nandan, M. Kozlowski, F. Diaz-Mitoma, and A. Kumar. 2001. The p38 mitogen-Activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages. J. Biol. Chem. 276: 13664- 13674.
51. Yi, A. K., J. G. Yoon, S. J. Yeo, S. C. Hong, B. K. English, and A. M. Krieg. 2002. Role of mitogen-Activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. J. Immunol. 168: 4711-4720.